
End Stage Renal Disease Market By Type(Calcium Succinate, Mk-3866, Others), By Product Type(Calcium-Based Phosphate Binders, Calcimimetics, Others), By Indication(End Stage Renal Disease (ESRD) Induced Hyperphosphatemia), By End User(Hospitals, Homecare, Others), By Region And Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, And Forecast 2023-2032
-
42357
-
Dec 2023
-
179
-
-
This report was compiled by Correspondence Linkedin | Detailed Market research Methodology Our methodology involves a mix of primary research, including interviews with leading mental health experts, and secondary research from reputable medical journals and databases. View Detailed Methodology Page
-
Quick Navigation
- End Stage Renal Disease Market Size, Share, Trends Analysis
- End-Stage Renal Disease Market Dynamics
- End-Stage Renal Disease Market Segmentation Analysis
- End Stage Renal Disease Industry Segments
- End-Stage Renal Disease Market Growth Opportunity
- End-Stage Renal Disease Market Regional Analysis
- End-Stage Renal Disease Industry By Region
- End-Stage Renal Disease Market Share Analysis
- End-Stage Renal Disease Industry Key Players
- End Stage Renal Disease Market Recent Development
- Report Scope
The stage Renal Disease Market size is predicted to reach approximately USD 391.8 Bn by 2032, from a valuation of USD 98.6 Bn in 2022, growing at a CAGR of 15.2% during the forecast period from 2023 to 2032.
End-stage renal disease (ESRD) is the final stage of chronic kidney disease, wherein kidneys have permanently lost over 90% of their capacity to filter blood and waste products.
Life-threatening renal conditions require kidney transplantation or renal replacement therapy such as dialysis to restore normal renal function and avoid fluid retention, toxin buildup, coma, or death. ESRD represents an enormous disruption to quality of life and requires intense medical management to sustain life through artificial filtration until a suitable kidney donor is obtained.
The End Stage Renal Disease Market is primarily driven by the rapidly aging population and the corresponding rise in chronic kidney diseases. More than half a million Americans suffer from end-stage renal disease (ESRD) which is often known as kidney failure. The mortality rates of patients range from 20 to 50 percent in 24 months. hyperkalemia as one of their primary factors.
Chronic Kidney Disease (CKD) is a significant source of reduced quality of life and premature mortality, impacting an estimated 37 million Americans - with approximately 90% of those with kidney disease not knowing they have it. These figures underscore the need for proactive medical intervention, emphasizing screening and appropriate antibiotic treatment for ESRD patients.
With increasing age comes kidneys that lose the capacity to filter waste out of the bloodstream efficiently. Diabetes and hypertension, two leading causes of End Stage Renal Disease, are also projected to drive this market growth.
According to WHO estimates, 422 million people globally currently suffer from diabetes. Unhealthy lifestyles and excessive alcohol and tobacco use further increase susceptibility. From a treatment perspective, the expanding base of patients requiring dialysis segments and kidney transplants will spur the demand for associated surgical procedures and medical devices like stents and catheters. Government initiatives to improve reimbursement policies and access to treatment are another contributory factor.
Accepted by the U.S. FDA in January 2023, a supplemental New Drug Application (sNDA) for Jardiance (empagliflozin) tablets has been acknowledged. Created in collaboration with Boehringer Ingelheim and Eli Lilly and Company The proposal is focused on the possible use of Jardiance as a treatment targeted at reducing the possibility of chronic kidney disease (CKD) progress and death from cardiovascular disease in patients with CKD.
More research is needed to find more efficient treatments as well as devices to help ESRD patients. Investments in R&D activities to improve dialysis efficiency and kidney transplant success rates also need a push.
In response to this, AstraZeneca is advancing Chronic Kidney Disease (CKD) research, conducting the largest-ever CKD exome sequencing study with Columbia University, investing in advanced models like 3D bioprinting, and exploring next-gen therapeutics.
Moreover, at the American Society of Nephrology’s Kidney Week 2023, a study presented by Yan Zhang, Ph., revealed that hemodiafiltration, compared to hemodialysis, is associated with a 22% lower risk of all-cause mortality in adult patients. The findings align with the CONVINCE trial, suggesting a significant survival advantage in real-world settings, supported by Fresenius Medical Care.
As the End Stage Renal Disease (ESRD) market evolves, these advancements become crucial in enhancing patient care and addressing the growing challenges in managing kidney-related health issues.
The End Stage Renal Disease Market presents opportunities for innovations and expansions in dialysis services and products as the prevalence of chronic kidney disease increases globally. Key companies can pursue growth through emerging dialysis modalities like peritoneal dialysis which offers patient convenience and flexibility. Further opportunities exist in developing improved hemodialysis machines and dialyzers for efficiency and portability allowing dialysis at home instead of clinics.
End-Stage Renal Disease Market Dynamics
CKD Patient Increase Accelerates ESRD Market Growth
The rising number of people suffering from Chronic Kidney Disease (CKD) is the main factor in the explosive growth of the market for End Stage Renal Disease (ESRD) market. As CKD grows more severe, it's often the root cause of ESRD and calls for treatment like dialysis as well as kidney transplantation. The increasing CKD prevalence, owing to factors like the aging population and unhealthy lifestyles, results in a higher incidence of ESRD.
This trend is not only escalating the demand for ESRD treatments and services but also prompting healthcare systems to improve and expand their renal care facilities. The ongoing increase in CKD patients forecasts sustained expansion of the ESRD market, with a focus on both managing the disease and enhancing the quality of patient care.
Awareness and Healthcare Access Boost ESRD Market in Developing Regions
Rising awareness for early diagnosis of ESRD and improving access to healthcare in developing regions are significantly influencing the market. The increased awareness can lead the way to faster detection as well as treatment which may slow down the progression of the disease and enhance the patient's outcomes.
In regions in the developing world where access to healthcare is typically restricted, advances in the healthcare infrastructure and services enable more patients to receive prompt and efficient ESRD treatment. This trend is not only enhancing the quality of life for patients but also expanding the market reach into previously underserved areas. The long-term implication is a more equitable global ESRD market, with increased treatment availability and improved health outcomes in developing regions.
Diabetes and Hypertension Prevalence Drive ESRD Market Expansion
The rising prevalence of diabetes and hypertension, which are major risk factors for End-Stage Renal Disease (ESRD), is a key driver of market growth. These conditions can cause severe kidney damage that results in ESRD. Due to the worldwide increase in hypertension and diabetes, in part because of lifestyle changes and a rise in obesity the prevalence of ESRD is increasing too.
This correlation is driving the demand for ESRD treatments and services, as healthcare systems strive to manage this growing patient population. The trend indicates a market increasingly focused on addressing the renal complications of these common chronic diseases, suggesting a continued need for advanced ESRD care and innovative treatment solutions.
High Cost of Treatment Restrains End-Stage Renal Disease Market Growth
Treatment for ESRD usually requires expensive long-term treatments such as dialysis or even kidney transplantation. The constant costs of dialysis are based on medical and apparatus, in addition to frequent visits to the hospital put an enormous burden on medical specialists as well as patients.
The cost of kidney transplants as well as post-operative care like surgeries, immunosuppressive medicines, and post-operative treatment can be considerable. The price for these procedures can be costly for some patients, particularly in areas in which there is a deficiency of insurance funds or healthcare, which restricts the expansion of the market.
Limited Availability and Accessibility of Treatment Options Limit End end-stage renal Disease Market Growth
The limited availability and accessibility of treatment options also pose significant barriers to the growth of the End Stage Renal Disease market. In many regions, especially in developing countries, there is a scarcity of healthcare facilities equipped to provide comprehensive ESRD care. This includes a lack of dialysis centers and limited access to transplant facilities.
Moreover, geographical barriers and transportation issues can make it difficult for patients to regularly access necessary treatment. The shortage of healthcare professionals specializing in nephrology further exacerbates the situation. These limitations in accessibility and availability of treatment options hinder the effective management of ESRD and restrict the market's potential to grow.
End-Stage Renal Disease Market Segmentation Analysis
By Type Analysis
Calcium Succinate leads the type segment in the End Stage Renal Disease (ESRD) market. It's primarily used to manage hyperphosphatemia, a common issue in ESRD patients. This dominance is attributed to its effectiveness in reducing phosphate levels and its relative safety profile. Its widespread use is further supported by its affordability and accessibility compared to newer, more expensive treatments.
Other medications like Mk-3866, Pacritinib, Sanguinate, and Tesidolumab are being developed or used for various complications associated with ESRD. While these treatments are significant for specific needs and patient populations, they currently hold a smaller market share compared to established treatments like Calcium Succinate. Their future market impact will depend on clinical trial outcomes, regulatory approvals, and adoption in clinical practice.
By Product Type Analysis
Calcium-based phosphate binders are the most used product type in the ESRD market. They work by binding to dietary phosphate, making it insoluble and reducing its absorption. Their dominance is due to their efficacy in managing hyperphosphatemia, a critical issue in ESRD, and their cost-effectiveness compared to other binders.
Calcimimetics is used to treat secondary hyperparathyroidism in ESRD patients. Vitamin D and sterols are important for managing bone health in ESRD. Potassium binders help in managing hyperkalemia. Each of these items has a significant role to contribute to addressing the various needs of ESRD patients. This comprehensive approach allows for not only the reduction of certain problems, however, but also helps to improve the quality of general well-being.
By Indication Analysis
Hyperphosphatemia management is a primary concern in ESRD, leading this indication segment. Phosphate buildup, due to reduced kidney function, necessitates the use of phosphate binders and dietary management. Clinicians typically use a multidisciplinary approach that combines pharmaceutical treatment with careful food regimens to achieve optimal control of hyperphosphatemia among patients suffering from end-stage renal disease.
Hyperkalemia and hyperparathyroidism are frequent in ESRD patients. Managing these conditions involves a combination of medications like calcimimetics for hyperparathyroidism and potassium binders for hyperkalemia, alongside other supportive treatments. Close monitoring of biochemical markers and regular adjustments to the therapeutic regimen are essential to achieve an optimal balance.
By End User Analysis
Hospitals are the primary end-users in the ESRD market, attributed to the need for specialized care and the complexity of treatments. Hospitals are equipped with the necessary infrastructure for ESRD management, including dialysis units.
The critical role of hospitals extends beyond treatment to encompass comprehensive patient education, continuous monitoring, and the coordination of multidisciplinary healthcare teams, ensuring a holistic approach to managing the end-stage renal disease.Home care is growing due to advancements in home dialysis technology. Specialty clinics offer focused care for ESRD patients. Other end-users, such as long-term care facilities and community clinics, play an essential role in extending ESRD care beyond acute settings, emphasizing continuity of care and support for patients transitioning between different healthcare environments.
End Stage Renal Disease Industry Segments
By Type
- Calcium Succinate
- Mk-3866
- Pacritinib
- Sanguinate
- Tesidolumab
- Others
By Product Type
By Indication
- End Stage Renal Disease (ESRD) Induced Hyperphosphatemia
- End Stage Renal Disease (ESRD) Induced Hyperparathyroidism
- End Stage Renal Disease (ESRD) Induced Hyperkalaemia
By End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
End-Stage Renal Disease Market Growth Opportunity
Growing Demand for Dialysis Offers Growth Opportunity in End-Stage Renal Disease Market
The rising demand for dialysis therapy is a major potential for growth in the end-of-stage kidney condition (ESRD) market. The increase in the incidence of kidney-related illnesses due to factors such as hypertension, diabetes, and the aging of populations has increased the prevalence of ESRD.
This has led to the rising need for dialysis to be a permanent treatment option for patients suffering from ESRD. Recent studies have shown an increased amount of people who require dialysis. This suggests the possibility for the expansion of dialysis-related hemodialysis in addition to products and services to treat the peritoneal area.
Regional Expansion and Market Penetration Fuel Growth in the End-stage Renal Disease Market
Regional expansion and market penetration strategies are key drivers for growth in the end-stage renal disease market. There's a noticeable trend of healthcare providers and medical companies expanding their services and products into new regions, particularly in emerging markets where healthcare infrastructure is developing.
This expansion is not only about establishing new facilities but also involves adapting services and products to meet local needs and regulatory requirements. The move into underpenetrated markets, accompanied by strategic partnerships and localized service offerings, indicates significant growth potential, as it broadens the availability of ESRD treatments and captures new patient populations.
End-Stage Renal Disease Market Regional Analysis
Asia-Pacific Dominates with 41.60% Market Share
Asia-Pacific's substantial 41.60 percent share of the world's End Stage Renal Disease (ESRD) Market is mainly driven by its vast and growing population that is more prone to chronic illnesses that affect kidneys, for example.
The rising prevalence of hypertension and diabetes which are the main contributors to ESRD in large nations such as China and India can contribute to the increasing incidence in the development of the illness. Additionally, the improving healthcare infrastructure and growing accessibility to renal care services in the region enhance its market dominance.
The market dynamics in Asia-Pacific are influenced by the rising healthcare expenditure and the growing awareness about kidney diseases and their management. The expansion of healthcare insurance coverage and government initiatives in countries such as Japan and South Korea further support the treatment and management of ESRD. Moreover, the increasing investment in healthcare technologies, including dialysis and transplantation facilities, plays a crucial role in the region’s market growth.
Looking forward, the ESRD market in Asia-Pacific is expected to continue growing. Furthermore, advancements in renal disease management and the introduction of innovative treatment solutions are expected to boost the market's growth in the region.
Europe’s Advanced Healthcare Systems and Patient-Centric Approaches
Europe's ESRD market is driven by its advanced healthcare systems and patient-centric approaches to disease management. The region's emphasis on early diagnosis and treatment, combined with high standards of renal care and a strong focus on research and development, contributes to the market's growth. European countries also benefit from well-structured healthcare policies and funding, supporting the management of chronic diseases like ESRD.
North America’s Innovation and High Standards of Care
In North America, particularly in the United States, the ESRD market benefits from the region's innovative medical technology and high standards of healthcare. The presence of leading healthcare companies, along with significant investments in research and novel therapies for kidney diseases, supports the market. The region's advanced healthcare infrastructure, combined with initiatives to enhance renal disease awareness and management, plays a key role in the market's dynamics.
End-Stage Renal Disease Industry By Region
North America
- The US
- Canada
- Rest of North America
Europe
- Germany
- France
- The UK
- Spain
- Italy
- Russia
- Netherlands
- Rest of Europe
Asia-Pacific
- China
- Japan
- South Korea
- India
- New Zealand
- Singapore
- Thailand
- Vietnam
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
In the End Stage Renal Disease (ESRD) Market, the companies listed are central to the sector's advancements and patient care strategies. Nipro Corp., Fresenius Medical Care AG & Co. KGaA, and Baxter International, Inc. stand out as leaders in dialysis equipment and services, reflecting the market's focus on providing comprehensive renal care solutions and technologies for ESRD management.
Medtronic Plc and B. Braun Melsungen AG, with their expertise in medical devices and pharmaceuticals, play pivotal roles in advancing hemodialysis and peritoneal dialysis technologies. Their products and services emphasize the importance of innovation in enhancing patient outcomes and treatment efficiency.
BD (Becton, Dickinson, and Company) and Asahi Kasei Medical Co., Ltd, known for their contributions to medical technology and materials, are crucial in the development of high-quality dialysis equipment components, contributing to the overall safety and effectiveness of renal care.
Cantel Medical and Nikkiso Co., Ltd, while smaller in comparison, contribute significantly through specialized products and services, showcasing the industry's diversity in addressing various aspects of ESRD treatment. JMS Co. Ltd and AngioDynamics, Inc., with their niche products and services, further underscore the market's breadth, catering to specific needs within ESRD treatment.
B. Braun Melsungen AG and Fresenius SE & Co. KGaA, with their extensive global presence, demonstrate the significance of scalable solutions and international reach in addressing the growing global demand for ESRD treatments. Dialysis Clinics, Inc. (a part of Baxter) and Medtronic PLC, with their focus on patient-centric care and innovative treatment modalities, highlight the industry's shift towards patient comfort and improved quality of life in ESRD management.
Collectively, these companies drive the End Stage Renal Disease Market's growth, representing a spectrum of strategies from advancing dialysis technology to enhancing patient care and treatment accessibility, crucial for addressing the complex needs of ESRD patients worldwide.
End-Stage Renal Disease Industry Key Players
- Nipro Corporation
- Fresenius Medical Care AG & Co. KGaA
- Baxter International, Inc.
- Medtronic Plc
- B. Braun Melsungen AG
- BD
- Asahi Kasei Medical Co., Ltd
- Cantel Medical
- Nikkiso Co., Ltd
- JMS Co. Ltd
- AngioDynamics, Inc.
- B. Braun Melsungen AG
- Fresenius SE & Co. KGaA
- Dialysis Clinics, Inc. (Baxter)
- Medtronic PLC
- Novartis AG
End Stage Renal Disease Market Recent Development
- In 2023, British health data start-up Gendius received a UKCA mark for its digital pre-screening technology, the CKD Screening Prioritizer (CSP). The CSP is now a registered medical device in the UK and uses readily available data to predict whether a patient with type 2 diabetes is likely to be experiencing kidney dysfunction.
- In August 2023, Kalium Health, a Cambridge University spinout, signed a significant Research and Development (R&D) partnership to develop an at-home blood potassium test.
- In July 2023, Holly Vossel, the Kidney Care Choices (KCC) model, which is a reimbursement stream aimed at improving coordinated care and education for patients with kidney disease.
- In June 2023, Dr. Shen Ren, an assistant professor of mechanical engineering at Seattle University, and his team, in collaboration with the UW Center for Dialysis Innovation (CDI) and the Northwest Kidney Centers (NWKC), embarked on a groundbreaking project to develop a portable, artificial kidney.
Report Scope
Report Features Description Market Value (2022) USD 98.6 Billion Forecast Revenue (2032) USD 391.8 Billion CAGR (2023-2032) 15.2% Base Year for Estimation 2022 Historic Period 2016-2022 Forecast Period 2023-2032 Report Coverage Revenue Forecast, Market Dynamics, COVID-19 Impact, Competitive Landscape, Recent Developments Segments Covered By Type(Calcium Succinate, Mk-3866, Pacritinib, Sanguinate, Tesidolumab, Others), By Product Type(Calcium-Based Phosphate Binders, Calcimimetics, Vitamin D, Sterols, Potassium Binders, Others), By Indication(End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperkalaemia), By End User(Hospitals, Homecare, Specialty Clinics, Others) Regional Analysis North America - The US, Canada, Rest of North America, Europe - Germany, France, The UK, Spain, Italy, Russia, Netherlands, Rest of Europe, Asia-Pacific - China, Japan, South Korea, India, New Zealand, Singapore, Thailand, Vietnam, Rest of Asia Pacific, Latin America - Brazil, Mexico, Rest of Latin America, Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa Competitive Landscape Nipro Corporation, Fresenius Medical Care AG & Co. KGaA, Baxter International, Inc., Medtronic Plc, B. Braun Melsungen AG, BD, Asahi Kasei Medical Co., Ltd, Cantel Medical, JMS Co. Ltd, AngioDynamics, Inc., B. Braun Melsungen AG, Fresenius SE & Co. KGaA, Dialysis Clinics, Inc. (Baxter), Medtronic PLC, Novartis AG Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. Purchase Options We have three licenses to opt for Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF) -
-
- Nipro Corporation
- Fresenius Medical Care AG & Co. KGaA
- Baxter International, Inc.
- Medtronic Plc
- B. Braun Melsungen AG
- BD
- Asahi Kasei Medical Co., Ltd
- Cantel Medical
- Nikkiso Co., Ltd
- JMS Co. Ltd
- AngioDynamics, Inc.
- B. Braun Melsungen AG
- Fresenius SE & Co. KGaA
- Dialysis Clinics, Inc. (Baxter)
- Medtronic PLC
- Novartis AG